Likelike personal page - To The Moon

Likelike

Likelike

Like like

109Follow

29Followers

0Topic

0Badge

2024-10-28

2024-10-21

2023-02-02

thanks 😊

2021-09-23

Nio niu (bull)ah!

Sorry, the original content has been removed

2021-09-23

Pfizer can reach $50 by Oct....i wish

Sorry, the original content has been removed

2021-09-22

Maybe Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....

Sorry, the original content has been removed

2021-09-13

ford should be a $15 share..i wish

Ford Motor Says Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer

2021-09-13

sold first maybe buy later <8,pls like n share your comments thanks

Ocugen shares surged more than 13% in Monday morning trading

2021-09-12

$19X by end year

Sorry, the original content has been removed

2021-09-04

$NIO Inc.(NIO)$hope to reach half Tesla price haha

2021-09-01

should buy sundial

U.S. pot producer Terrascend to buy rival Gage Growth for $545 mln - sources

2021-08-31

$Sundial Growers Inc.(SNDL)$this month need it reach$1 pls......God Allah Buddha Brahman help help.....

2021-08-31

Alibaba or Sea Ltd reach $500 first??

Sorry, the original content has been removed

2021-08-27

when bitcoin rise back to $60k????

Crypto stocks surged in morning trading

2021-08-27

when nio xpeng rise to $50???

Tesla Wants to Become an Electricity Retailer in Texas. What To Know.

2021-08-27

when nio xpeng rise to$50???

Sorry, the original content has been removed

2021-08-23

pfizer up up

Sorry, the original content has been removed

2021-08-20

good

Sorry, the original content has been removed

2021-08-20

pfizer rules

Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?

2021-08-20

when sundial rises????

2 No-Brainer Stocks to Buy in the Cannabis Sector

Go to Tiger App to see more news

Invest in Global Markets with Tiger Brokers!

Open App

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4091708143350050","uuid":"4091708143350050","gmtCreate":1628605862019,"gmtModify":1632926032280,"name":"Likelike","pinyin":"likelike","introduction":"","introductionEn":null,"signature":"Like like","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":29,"headSize":109,"tweetSize":45,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.32%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.45%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":364998089552032,"gmtCreate":1730121102013,"gmtModify":1730121106849,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/97f1fb631fa117474fa95250eb4e31cd","width":"870","height":"1772"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/364998089552032","isVote":1,"tweetType":1,"viewCount":906,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"10000000000010968","authorId":"10000000000010968","name":"Tiger_CashBoostAccount","avatar":"https://community-static.tradeup.com/news/ae2d4002ef9664aba005cb3020f416f5","crmLevel":1,"crmLevelSwitch":0,"idStr":"10000000000010968","authorIdStr":"10000000000010968"},"content":"Great job on your latest stock market success! Your commitment to research and analysis is evident in your results. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳💹💰🤩 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","text":"Great job on your latest stock market success! Your commitment to research and analysis is evident in your results. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳💹💰🤩 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","html":"Great job on your latest stock market success! Your commitment to research and analysis is evident in your results. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳💹💰🤩 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":362453877051392,"gmtCreate":1729525626876,"gmtModify":1729525631290,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/f3b0375635ab832502e55203cfa6ae4b","width":"1080","height":"2379"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/362453877051392","isVote":1,"tweetType":1,"viewCount":950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9955145856,"gmtCreate":1675301485576,"gmtModify":1676538990786,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;thanks&nbsp;😊&nbsp;","listText":"&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;thanks&nbsp;😊&nbsp;","text":"thanks 😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9955145856","isVote":1,"tweetType":1,"viewCount":1044,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863228838,"gmtCreate":1632400543624,"gmtModify":1676530772779,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Nio niu (bull)ah!","listText":"Nio niu (bull)ah!","text":"Nio niu (bull)ah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/863228838","repostId":"1135139549","repostType":4,"isVote":1,"tweetType":1,"viewCount":1268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863229400,"gmtCreate":1632400374400,"gmtModify":1676530772716,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Pfizer can reach $50 by Oct....i wish","listText":"Pfizer can reach $50 by Oct....i wish","text":"Pfizer can reach $50 by Oct....i wish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/863229400","repostId":"1133566174","repostType":4,"isVote":1,"tweetType":1,"viewCount":1272,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4092216435500580","authorId":"4092216435500580","name":"SimonSim","avatar":"https://static.tigerbbs.com/f2870d5ab54ba75f2d74ad8cb044473a","crmLevel":2,"crmLevelSwitch":0,"idStr":"4092216435500580","authorIdStr":"4092216435500580"},"content":"[Happy] [Happy] [Happy]","text":"[Happy] [Happy] [Happy]","html":"[Happy] [Happy] [Happy]"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869784588,"gmtCreate":1632322282944,"gmtModify":1676530752993,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Maybe&nbsp;Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","listText":"Maybe&nbsp;Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","text":"Maybe Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/869784588","repostId":"1143821004","repostType":4,"isVote":1,"tweetType":1,"viewCount":1283,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3580536610076415","authorId":"3580536610076415","name":"BettyT","avatar":"https://static.tigerbbs.com/6a4dfe2f455acd2af7629f83ce30e20c","crmLevel":5,"crmLevelSwitch":0,"idStr":"3580536610076415","authorIdStr":"3580536610076415"},"content":"diversified ? Haha ??","text":"diversified ? Haha ??","html":"diversified ? Haha ??"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886336965,"gmtCreate":1631549461457,"gmtModify":1676530574165,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"ford should be a $15 share..i wish","listText":"ford should be a $15 share..i wish","text":"ford should be a $15 share..i wish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/886336965","repostId":"2167658404","repostType":2,"repost":{"id":"2167658404","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1631545694,"share":"https://ttm.financial/m/news/2167658404?lang=&edition=full_marsco","pubTime":"2021-09-13 23:08","market":"us","language":"en","title":"Ford Motor Says Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2167658404","media":"T-Reuters","summary":"Ford Motor Co :Ford Motor Co - Mike Amend Starts With Ford Today As The New Chief Digital And Inform","content":"<html><body><p>Ford Motor Co <f.n>:Ford Motor Co - Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer.Further Company Coverage: F.N. ((Reuters.Briefs@Thomsonreuters.Com;)).</f.n></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford Motor Says Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord Motor Says Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-09-13 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Ford Motor Co <f.n>:Ford Motor Co - Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer.Further Company Coverage: F.N. ((Reuters.Briefs@Thomsonreuters.Com;)).</f.n></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DLR":"数字房地产信托公司","F":"福特汽车","III":"信息服务","NGD":"New Gold"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167658404","content_text":"Ford Motor Co :Ford Motor Co - Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer.Further Company Coverage: F.N. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1},"isVote":1,"tweetType":1,"viewCount":1292,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3586655655659820","authorId":"3586655655659820","name":"sunshine138","avatar":"https://static.tigerbbs.com/23149c63a63bfeec1572cc27e1322750","crmLevel":3,"crmLevelSwitch":0,"idStr":"3586655655659820","authorIdStr":"3586655655659820"},"content":"When will it move there","text":"When will it move there","html":"When will it move there"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886333560,"gmtCreate":1631549154550,"gmtModify":1676530574110,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"sold first maybe buy later &lt;8,pls like n share your comments&nbsp;thanks","listText":"sold first maybe buy later &lt;8,pls like n share your comments&nbsp;thanks","text":"sold first maybe buy later <8,pls like n share your comments thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/886333560","repostId":"1126978010","repostType":4,"repost":{"id":"1126978010","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631544701,"share":"https://ttm.financial/m/news/1126978010?lang=&edition=full_marsco","pubTime":"2021-09-13 22:51","market":"us","language":"en","title":"Ocugen shares surged more than 13% in Monday morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126978010","media":"Tiger Newspress","summary":"Ocugen shares surged more than 13% in Monday morning trading.\n\nVarious companies have been engaged i","content":"<p>Ocugen shares surged more than 13%&nbsp;in Monday morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/8fcba6c91ee88af0dd90608a79065282\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Various companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.</p>\n<p>Clinical-stage biotech firm Ocugen (<b>OCGN</b>) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.</p>\n<p>The announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of&nbsp;$18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.</p>\n<p>As rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.</p>\n<p>However, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.</p>\n<p><b>Delta Variant Concerns Pushing OCGN Stock up</b></p>\n<p>Newly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.</p>\n<p>This new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.</p>\n<p>According to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.</p>\n<p><b>Short-term Catalyst behind the Sudden Spike</b></p>\n<p>Ocugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.</p>\n<p>Health Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.</p>\n<p>Moreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.</p>\n<p><b>Ocugen Needs to Progress</b></p>\n<p>The biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.</p>\n<p>On top of that, it posted a&nbsp;net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.</p>\n<p>As of June 30, cash and cash equivalents stood at $115.6 million.</p>\n<p><b>Wall Street’s Take</b></p>\n<p>As per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.</p>\n<p>The&nbsp;average OCGN price target&nbsp;is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.</p>\n<p><img src=\"https://static.tigerbbs.com/9c696ea686fdeaa8d6550e1282efebf7\" tg-width=\"1099\" tg-height=\"374\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Bottom Line</b></p>\n<p>Ocugen stock could very well profit from the mounting global concerns about the Delta variant.</p>\n<p>There might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.</p>\n<p>It’s an interesting play, but not without risk.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged more than 13% in Monday morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged more than 13% in Monday morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-13 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocugen shares surged more than 13%&nbsp;in Monday morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/8fcba6c91ee88af0dd90608a79065282\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Various companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.</p>\n<p>Clinical-stage biotech firm Ocugen (<b>OCGN</b>) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.</p>\n<p>The announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of&nbsp;$18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.</p>\n<p>As rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.</p>\n<p>However, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.</p>\n<p><b>Delta Variant Concerns Pushing OCGN Stock up</b></p>\n<p>Newly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.</p>\n<p>This new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.</p>\n<p>According to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.</p>\n<p><b>Short-term Catalyst behind the Sudden Spike</b></p>\n<p>Ocugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.</p>\n<p>Health Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.</p>\n<p>Moreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.</p>\n<p><b>Ocugen Needs to Progress</b></p>\n<p>The biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.</p>\n<p>On top of that, it posted a&nbsp;net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.</p>\n<p>As of June 30, cash and cash equivalents stood at $115.6 million.</p>\n<p><b>Wall Street’s Take</b></p>\n<p>As per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.</p>\n<p>The&nbsp;average OCGN price target&nbsp;is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.</p>\n<p><img src=\"https://static.tigerbbs.com/9c696ea686fdeaa8d6550e1282efebf7\" tg-width=\"1099\" tg-height=\"374\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Bottom Line</b></p>\n<p>Ocugen stock could very well profit from the mounting global concerns about the Delta variant.</p>\n<p>There might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.</p>\n<p>It’s an interesting play, but not without risk.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126978010","content_text":"Ocugen shares surged more than 13% in Monday morning trading.\n\nVarious companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.\nClinical-stage biotech firm Ocugen (OCGN) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.\nThe announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of $18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.\nAs rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.\nHowever, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.\nDelta Variant Concerns Pushing OCGN Stock up\nNewly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.\nThis new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.\nAccording to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.\nShort-term Catalyst behind the Sudden Spike\nOcugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.\nHealth Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.\nMoreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.\nOcugen Needs to Progress\nThe biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.\nOn top of that, it posted a net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.\nAs of June 30, cash and cash equivalents stood at $115.6 million.\nWall Street’s Take\nAs per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.\nThe average OCGN price target is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.\n\nBottom Line\nOcugen stock could very well profit from the mounting global concerns about the Delta variant.\nThere might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.\nIt’s an interesting play, but not without risk.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888392488,"gmtCreate":1631431444744,"gmtModify":1676530547708,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"$19X&nbsp;by end year","listText":"$19X&nbsp;by end year","text":"$19X by end year","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888392488","repostId":"2166904370","repostType":4,"isVote":1,"tweetType":1,"viewCount":1092,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814358162,"gmtCreate":1630768928456,"gmtModify":1676530392740,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>hope to reach half Tesla price haha","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>hope to reach half Tesla price haha","text":"$NIO Inc.(NIO)$hope to reach half Tesla price haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/814358162","isVote":1,"tweetType":1,"viewCount":1467,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":1,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"content":"Nio to the moon??????","text":"Nio to the moon??????","html":"Nio to the moon??????"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816429803,"gmtCreate":1630515201002,"gmtModify":1676530328185,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"should&nbsp; buy sundial&nbsp;","listText":"should&nbsp; buy sundial&nbsp;","text":"should buy sundial","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816429803","repostId":"2164890060","repostType":4,"repost":{"id":"2164890060","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630508469,"share":"https://ttm.financial/m/news/2164890060?lang=&edition=full_marsco","pubTime":"2021-09-01 23:01","market":"us","language":"en","title":"U.S. pot producer Terrascend to buy rival Gage Growth for $545 mln - sources","url":"https://stock-news.laohu8.com/highlight/detail?id=2164890060","media":"Reuters","summary":"Sept 1 (Reuters) - Terrascend will buy Michigan-based rival Gage Growth Corp, backed by prominent ca","content":"<p>Sept 1 (Reuters) - Terrascend will buy Michigan-based rival Gage Growth Corp, backed by prominent cannabis investor Jason Wilde, for around $545 million, the U.S. pot producer said on Wednesday.</p>\n<p>Dealmaking in the U.S. cannabis industry has heated up this year as companies bank on Democrats' promises to reform marijuana laws and potentially legalize the plant at the federal level.</p>\n<p>However, little progress has been made so far and weed stocks have fallen off a cliff in recent months. Gage Growth shares have plunged about 22% up to its last close, since its direct Canadian listing in April.</p>\n<p>Gage Growth, which closed its first day of trading at C$2.89 ($2.29) on April 6, will receive an implied consideration of C$2.66 per share in the merger.</p>\n<p>The combined company will have operations in five U.S. states and Canada, including seven cultivation and processing facilities and 23 operating dispensaries in the two countries, Terrascend said in a statement.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. pot producer Terrascend to buy rival Gage Growth for $545 mln - sources</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. pot producer Terrascend to buy rival Gage Growth for $545 mln - sources\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-01 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sept 1 (Reuters) - Terrascend will buy Michigan-based rival Gage Growth Corp, backed by prominent cannabis investor Jason Wilde, for around $545 million, the U.S. pot producer said on Wednesday.</p>\n<p>Dealmaking in the U.S. cannabis industry has heated up this year as companies bank on Democrats' promises to reform marijuana laws and potentially legalize the plant at the federal level.</p>\n<p>However, little progress has been made so far and weed stocks have fallen off a cliff in recent months. Gage Growth shares have plunged about 22% up to its last close, since its direct Canadian listing in April.</p>\n<p>Gage Growth, which closed its first day of trading at C$2.89 ($2.29) on April 6, will receive an implied consideration of C$2.66 per share in the merger.</p>\n<p>The combined company will have operations in five U.S. states and Canada, including seven cultivation and processing facilities and 23 operating dispensaries in the two countries, Terrascend said in a statement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164890060","content_text":"Sept 1 (Reuters) - Terrascend will buy Michigan-based rival Gage Growth Corp, backed by prominent cannabis investor Jason Wilde, for around $545 million, the U.S. pot producer said on Wednesday.\nDealmaking in the U.S. cannabis industry has heated up this year as companies bank on Democrats' promises to reform marijuana laws and potentially legalize the plant at the federal level.\nHowever, little progress has been made so far and weed stocks have fallen off a cliff in recent months. Gage Growth shares have plunged about 22% up to its last close, since its direct Canadian listing in April.\nGage Growth, which closed its first day of trading at C$2.89 ($2.29) on April 6, will receive an implied consideration of C$2.66 per share in the merger.\nThe combined company will have operations in five U.S. states and Canada, including seven cultivation and processing facilities and 23 operating dispensaries in the two countries, Terrascend said in a statement.","news_type":1},"isVote":1,"tweetType":1,"viewCount":734,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818232208,"gmtCreate":1630412068404,"gmtModify":1676530295824,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>this month need it reach$1 pls......God Allah Buddha Brahman help help.....","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>this month need it reach$1 pls......God Allah Buddha Brahman help help.....","text":"$Sundial Growers Inc.(SNDL)$this month need it reach$1 pls......God Allah Buddha Brahman help help.....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818232208","isVote":1,"tweetType":1,"viewCount":832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818294685,"gmtCreate":1630411172447,"gmtModify":1676530295627,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Alibaba or Sea Ltd reach $500 first??","listText":"Alibaba or Sea Ltd reach $500 first??","text":"Alibaba or Sea Ltd reach $500 first??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818294685","repostId":"2163859671","repostType":4,"isVote":1,"tweetType":1,"viewCount":979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819412201,"gmtCreate":1630086512203,"gmtModify":1676530221959,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when bitcoin rise back to $60k????","listText":"when bitcoin rise back to $60k????","text":"when bitcoin rise back to $60k????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/819412201","repostId":"1199074003","repostType":4,"repost":{"id":"1199074003","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630077382,"share":"https://ttm.financial/m/news/1199074003?lang=&edition=full_marsco","pubTime":"2021-08-27 23:16","market":"us","language":"en","title":"Crypto stocks surged in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199074003","media":"Tiger Newspress","summary":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,","content":"<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks surged in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks surged in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-27 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SOS":"SOS Limited","RIOT":"Riot Platforms","NCTY":"第九城市","COIN":"Coinbase Global, Inc.","EBON":"亿邦国际","BTBT":"Bit Digital, Inc.","MARA":"MARA Holdings","BTCM":"BIT Mining","CAN":"嘉楠科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199074003","content_text":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase and Paypal climbed between 1% and 13%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":584,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581978054709801","authorId":"3581978054709801","name":"Nickystonks","avatar":"https://static.tigerbbs.com/9ea10f153b0e264f05c7d19fcc08cdee","crmLevel":3,"crmLevelSwitch":0,"idStr":"3581978054709801","authorIdStr":"3581978054709801"},"content":"maybe. 50k is a resistance level. let's see if it breaks it","text":"maybe. 50k is a resistance level. let's see if it breaks it","html":"maybe. 50k is a resistance level. let's see if it breaks it"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819416733,"gmtCreate":1630086304922,"gmtModify":1676530221943,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when nio xpeng rise to $50???","listText":"when nio xpeng rise to $50???","text":"when nio xpeng rise to $50???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/819416733","repostId":"1165379113","repostType":4,"repost":{"id":"1165379113","kind":"news","pubTimestamp":1630075265,"share":"https://ttm.financial/m/news/1165379113?lang=&edition=full_marsco","pubTime":"2021-08-27 22:41","market":"us","language":"en","title":"Tesla Wants to Become an Electricity Retailer in Texas. What To Know.","url":"https://stock-news.laohu8.com/highlight/detail?id=1165379113","media":"Barrons","summary":"A Tesla subsidiary has applied to become an electricity retailer in Texas, moving to widen the energ","content":"<p>A Tesla subsidiary has applied to become an electricity retailer in Texas, moving to widen the energy ambitions of Elon Musk’s electric-vehicle company in a state with a power grid that came under scrutiny after failing in a February winter storm.</p>\n<p>Tesla Energy Ventures, a subsidiary of Tesla formed in late July, wants to sell power directly to customers as a retail electricity provider, according to an August 16 filing with the Texas Public Utility Commission.</p>\n<p>Shares in Tesla were 0.6% higher in U.S. premarket trading on Friday, outpacing a rise in futures for the&nbsp;Nasdaq 100&nbsp;index, of which Tesla is a component.</p>\n<p>Tesla also intends to build two massive utility-scale batteries to serve power companies in the state, according to Texas Monthly,which first reported the news&nbsp;on Thursday and said that the filing could be approved by November.</p>\n<p>One of those batteries would reportedly be located at a gigafactory outside Austin, where the Cybertruck and Model Y SUV are slated to be built, with another located outside Houston,based on a report from Bloomberg.</p>\n<p>Texas’ deregulated power grid includes well over 100 companies selling to consumers. The state’s power system came under the spotlight this winter, when&nbsp;a February storm&nbsp;left millions without electricity for several days.</p>\n<p>Tesla hoped to enter the Texas power market earlier, before the widespread blackouts in February, according to the Texas Monthly report.</p>\n<p>The company has a history of building utility-scale power storage, with developments in California and Australia, but becoming an electricity retailer in Texas would be a significant milestone in the expansion of Tesla’s energy division.</p>\n<p>“I can’t emphasize enough, I think long term, Tesla Energy will be of roughly the same size as Tesla Automotive,” Musk told investors last summer, after the company’s second-quarter earnings in July 2020.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Wants to Become an Electricity Retailer in Texas. What To Know.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Wants to Become an Electricity Retailer in Texas. What To Know.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 22:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-wants-to-become-an-electricity-retailer-in-texas-what-to-know-51630066304?mod=hp_DAY_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A Tesla subsidiary has applied to become an electricity retailer in Texas, moving to widen the energy ambitions of Elon Musk’s electric-vehicle company in a state with a power grid that came under ...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-wants-to-become-an-electricity-retailer-in-texas-what-to-know-51630066304?mod=hp_DAY_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-wants-to-become-an-electricity-retailer-in-texas-what-to-know-51630066304?mod=hp_DAY_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165379113","content_text":"A Tesla subsidiary has applied to become an electricity retailer in Texas, moving to widen the energy ambitions of Elon Musk’s electric-vehicle company in a state with a power grid that came under scrutiny after failing in a February winter storm.\nTesla Energy Ventures, a subsidiary of Tesla formed in late July, wants to sell power directly to customers as a retail electricity provider, according to an August 16 filing with the Texas Public Utility Commission.\nShares in Tesla were 0.6% higher in U.S. premarket trading on Friday, outpacing a rise in futures for the Nasdaq 100 index, of which Tesla is a component.\nTesla also intends to build two massive utility-scale batteries to serve power companies in the state, according to Texas Monthly,which first reported the news on Thursday and said that the filing could be approved by November.\nOne of those batteries would reportedly be located at a gigafactory outside Austin, where the Cybertruck and Model Y SUV are slated to be built, with another located outside Houston,based on a report from Bloomberg.\nTexas’ deregulated power grid includes well over 100 companies selling to consumers. The state’s power system came under the spotlight this winter, when a February storm left millions without electricity for several days.\nTesla hoped to enter the Texas power market earlier, before the widespread blackouts in February, according to the Texas Monthly report.\nThe company has a history of building utility-scale power storage, with developments in California and Australia, but becoming an electricity retailer in Texas would be a significant milestone in the expansion of Tesla’s energy division.\n“I can’t emphasize enough, I think long term, Tesla Energy will be of roughly the same size as Tesla Automotive,” Musk told investors last summer, after the company’s second-quarter earnings in July 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":449,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819418625,"gmtCreate":1630086116667,"gmtModify":1676530221910,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when nio xpeng rise to$50???","listText":"when nio xpeng rise to$50???","text":"when nio xpeng rise to$50???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/819418625","repostId":"2162021329","repostType":4,"isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835513111,"gmtCreate":1629726602833,"gmtModify":1676530112928,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"pfizer up up","listText":"pfizer up up","text":"pfizer up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/835513111","repostId":"1132832038","repostType":4,"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836618944,"gmtCreate":1629475034188,"gmtModify":1676530054850,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836618944","repostId":"2160471663","repostType":4,"isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836692550,"gmtCreate":1629473719270,"gmtModify":1676530054442,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"pfizer rules","listText":"pfizer rules","text":"pfizer rules","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836692550","repostId":"2160710721","repostType":4,"repost":{"id":"2160710721","kind":"news","pubTimestamp":1629473265,"share":"https://ttm.financial/m/news/2160710721?lang=&edition=full_marsco","pubTime":"2021-08-20 23:27","market":"us","language":"en","title":"Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?","url":"https://stock-news.laohu8.com/highlight/detail?id=2160710721","media":"Zacks","summary":"Moderna’s MRNA mRNA-based COVID-19 vaccine, mRNA-1273 is being investigated by the FDA and the U.S. ","content":"<p><b>Moderna</b>’s MRNA mRNA-based COVID-19 vaccine, mRNA-1273 is being investigated by the FDA and the U.S. Centers for Disease Control and Prevention (CDC) for higher risk of myocarditis, a rare condition of heart inflammation, in younger adults per a <a href=\"https://laohu8.com/S/WASH\">Washington</a> <a href=\"https://laohu8.com/S/POST\">Post</a> article. The article implies that the risk of myocarditis following inoculation with mRNA-1273 can be more than previously thought and is also higher than <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>/<b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b>’s mRNA-based vaccine, BNT162b.</p>\n<p>Per the same <a href=\"https://laohu8.com/S/WRE\">Washington</a> Post article, the claims of higher risk of myocarditis, especially for males below the age of 30 or so, following Moderna’s jab are majorly based on data from Canada. The same data suggests that vaccination with mRNA-1273 may increase the risk of incidence of myocarditis by 2.5-fold compared to BNT162b. U.S. health officials are currently reviewing the data as well as data generated in the <a href=\"https://laohu8.com/S/UBNK\">United</a> States for a possible link to higher risk of heart inflammation. The report stated that the officials believe it is too early to conclude and issue any kind of new or revised warning or recommendation for mRNA-1273.</p>\n<p>We note that Pfizer’s BNT162b is already leading the vaccination race with $11.3 billion sales in the first half of 2021 compared to nearly $6 billion of sales from mRNA-1273. Moreover, the anticipated sales for 2021 for BNT162b and mRNA-1273 stands at $33.5 billion and approximately $19.2 billion, respectively.</p>\n<p>Meanwhile, U.S. health officials have decided to start providing booster doses to the country’s citizens beginning in the first week of fall that will start on Sep 20. Amid rising support for booster doses for better protection against the Delta variant, the potential link to higher risk of heart inflammation may hurt demand for Moderna’s mRNA-1273, pushing it further back in the competition. Moreover, a few new COVID-19 vaccines may enter the U.S. markets this year, which will result in increased competition.</p>\n<p>Shares of Moderna fell 5.8% on Aug 19, following the reports on probe for higher risk of heart inflammation. The company’s shares have surged 259.4% so far this year against the industry’s decrease of 0.3%.</p>\n<p><img src=\"https://static.tigerbbs.com/01ae6084260e85bc39bcd6d72d8d9ae0\" tg-width=\"620\" tg-height=\"406\" referrerpolicy=\"no-referrer\"></p>\n<p>Image Source: Zacks Investment Research</p>\n<p>We note that the CDC concluded earlier in June that there is a “likely association” between mRNA-based COVID-19 vaccines and increased cases of heart inflammation, including myocarditis and pericarditis, in adolescents and younger adults. Heart inflammation was reported after the first dose of mRNA-1273 and BNT162b in a small proportion of individuals,which increased further following the second dose. However, similar inflammation cases were not reported following vaccination with <b>J&amp;J</b>’s JNJ adenovirus-based COVID-19 vaccine. Following the investigation, the labels of both mRNA-based vaccines were updated to include a warning label for increased risk of myocarditis.</p>\n<p>Meanwhile, the United States is not the only country to probe various risks with possible links to mRNA-based COVID-19 vaccines. Earlier this month, the European Medicines Agency initiated an investigation to study three new conditions found in a small proportion of individuals receiving mRNA-based vaccination.&nbsp;The individuals immunized with an mRNA-based vaccine reported that they developed either erythema multiforme (allergic skin reaction), glomerulonephritis (kidney inflammation) and/or nephrotic syndrome (renal disorder).</p>\n<h3><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> Price</h3>\n<p><img src=\"https://static.tigerbbs.com/33512fafdd460236be3b7bc6e113462a\" tg-width=\"545\" tg-height=\"257\" referrerpolicy=\"no-referrer\"></p>\n<p><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> price | Moderna, Inc. Quote</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 23:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-mrna-covid-19-jab-131601604.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna’s MRNA mRNA-based COVID-19 vaccine, mRNA-1273 is being investigated by the FDA and the U.S. Centers for Disease Control and Prevention (CDC) for higher risk of myocarditis, a rare condition of...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-mrna-covid-19-jab-131601604.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-mrna-covid-19-jab-131601604.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2160710721","content_text":"Moderna’s MRNA mRNA-based COVID-19 vaccine, mRNA-1273 is being investigated by the FDA and the U.S. Centers for Disease Control and Prevention (CDC) for higher risk of myocarditis, a rare condition of heart inflammation, in younger adults per a Washington Post article. The article implies that the risk of myocarditis following inoculation with mRNA-1273 can be more than previously thought and is also higher than Pfizer/BioNTech SE’s mRNA-based vaccine, BNT162b.\nPer the same Washington Post article, the claims of higher risk of myocarditis, especially for males below the age of 30 or so, following Moderna’s jab are majorly based on data from Canada. The same data suggests that vaccination with mRNA-1273 may increase the risk of incidence of myocarditis by 2.5-fold compared to BNT162b. U.S. health officials are currently reviewing the data as well as data generated in the United States for a possible link to higher risk of heart inflammation. The report stated that the officials believe it is too early to conclude and issue any kind of new or revised warning or recommendation for mRNA-1273.\nWe note that Pfizer’s BNT162b is already leading the vaccination race with $11.3 billion sales in the first half of 2021 compared to nearly $6 billion of sales from mRNA-1273. Moreover, the anticipated sales for 2021 for BNT162b and mRNA-1273 stands at $33.5 billion and approximately $19.2 billion, respectively.\nMeanwhile, U.S. health officials have decided to start providing booster doses to the country’s citizens beginning in the first week of fall that will start on Sep 20. Amid rising support for booster doses for better protection against the Delta variant, the potential link to higher risk of heart inflammation may hurt demand for Moderna’s mRNA-1273, pushing it further back in the competition. Moreover, a few new COVID-19 vaccines may enter the U.S. markets this year, which will result in increased competition.\nShares of Moderna fell 5.8% on Aug 19, following the reports on probe for higher risk of heart inflammation. The company’s shares have surged 259.4% so far this year against the industry’s decrease of 0.3%.\n\nImage Source: Zacks Investment Research\nWe note that the CDC concluded earlier in June that there is a “likely association” between mRNA-based COVID-19 vaccines and increased cases of heart inflammation, including myocarditis and pericarditis, in adolescents and younger adults. Heart inflammation was reported after the first dose of mRNA-1273 and BNT162b in a small proportion of individuals,which increased further following the second dose. However, similar inflammation cases were not reported following vaccination with J&J’s JNJ adenovirus-based COVID-19 vaccine. Following the investigation, the labels of both mRNA-based vaccines were updated to include a warning label for increased risk of myocarditis.\nMeanwhile, the United States is not the only country to probe various risks with possible links to mRNA-based COVID-19 vaccines. Earlier this month, the European Medicines Agency initiated an investigation to study three new conditions found in a small proportion of individuals receiving mRNA-based vaccination. The individuals immunized with an mRNA-based vaccine reported that they developed either erythema multiforme (allergic skin reaction), glomerulonephritis (kidney inflammation) and/or nephrotic syndrome (renal disorder).\nModerna, Inc. Price\n\nModerna, Inc. price | Moderna, Inc. Quote","news_type":1},"isVote":1,"tweetType":1,"viewCount":690,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836602761,"gmtCreate":1629473057753,"gmtModify":1676530054050,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when sundial rises????","listText":"when sundial rises????","text":"when sundial rises????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/836602761","repostId":"2160710591","repostType":4,"repost":{"id":"2160710591","kind":"highlight","pubTimestamp":1629470661,"share":"https://ttm.financial/m/news/2160710591?lang=&edition=full_marsco","pubTime":"2021-08-20 22:44","market":"us","language":"en","title":"2 No-Brainer Stocks to Buy in the Cannabis Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2160710591","media":"Motley Fool","summary":"A multi-state operator and an unconventional pot stock are both hot buys after reporting second-quarter earnings.","content":"<p>With state cannabis legalization ramping up across the U.S. and chances of federal legalization improving, investors might not want to lose out on this evolving sector. And outstanding second-quarter earnings from these two pot stocks in particular are excellent examples of the sector's high growth and exciting upside.</p>\n<p>Florida-based&nbsp;<b><a href=\"https://laohu8.com/S/TCNNF\">Trulieve Cannabis Corporation</a> </b>(OTC:&nbsp;TCNNF)<b>&nbsp;</b>reported another great quarter with outstanding revenue growth and positive earnings before interest, tax, depreciation, and amortization (EBITDA). Meanwhile, marijuana REIT<b> <a href=\"https://laohu8.com/S/IIPR\">Innovative Industrial Properties Inc</a> </b>(NYSE:&nbsp;IIPR) not only grew revenue, but also profits. Both are profitable companies expanding at a rapid rate to capture the cannabis market in the U.S. Let's dig into their second-quarter results and determine why they could be the best fit for your portfolio.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F639496%2Fpiggy-bank.jpeg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty&nbsp;Images.</p>\n<h2>Trulieve Cannabis' Q2 turned out even better than Q1</h2>\n<p>The credit for Trulieve's consistent performance mostly goes to its dominance in its home state, where it operates 85 stores. Its total revenue grew 78% year over year to $215 million. Adjusted EBITDA came in at $95 million, a 55% jump from the prior-year quarter. The company also generated net profits of $41 million, a 116% year-over-year increase. Q2 marks the company's 14th consecutive quarter of profitability, which is impressive considering how its Canadian counterparts are struggling to generate profits. </p>\n<p>For the six months ended June 30, the company has reached $409 million in revenue. If it continues to grow at this rate, I wouldn't be surprised if it ends 2021 with more than $1 billion. Note that these numbers don't include the revenue generated from the <b>Harvest Health &amp; Recreation&nbsp;</b>acquisition (once it completes), so expect them to climb even higher. Trulieve's purchase of Arizona-based Harvest Health in May pushed its store count to a total of 140, and it now boasts 3 million square feet of cultivation capacity in the U.S. The move also gives Trulieve access to markets in Arizona (which recently legalized recreational cannabis), Pennsylvania, and Maryland.</p>\n<p>Initially, investors were concerned with Trulieve's focus only on the Florida market; I was too. But a smart company knows to strengthen its roots first and then focus on expanding, and I applaud Trulieve for doing just that. The company used its capital resources well and continued generating profits first, without going on an acquisition spree. This made room for the Harvest acquisition to bolster Trulieve's presence in key cannabis markets across the nation. The company had cash and cash equivalents of $289 million and net debt of $118 million at the end of Q2. </p>\n<p>The only concern I have is that most of its revenue generated during the quarter came from the sale of medical cannabis products (all that's currently legal in Florida). Trulieve will need to add focus on recreational revenue going forward. Markets in <a href=\"https://laohu8.com/S/NWY\">New York</a>, Arizona, and New Jersey (which recently legalized recreational marijuana) present a tremendous opportunity for U.S. cannabis companies, but Trulieve has no stores in any of these states yet. </p>\n<p>Analysts expect a 132% upside for Trulieve's stock in the next 12 months, which I think is possible looking at the rate the company is growing. </p>\n<h2>This REIT's stock popped after another strong quarter</h2>\n<p>Innovative Industrial Properties is not directly linked to cannabis, but management has taken good advantage of the marijuana boom in the U.S. Its business model, in which it acquires properties from medical cannabis companies and leases them back to the sellers, has worked wonders for both parties; because cannabis is illegal at the federal level in the U.S., access to capital can be hard for marijuana companies to find in other ways. Besides allowing investors indirect access to the industry, Innovative is also a real estate investment trust (or REIT), meaning it is mandated by law to pay 90% of its taxable income as dividends.&nbsp;</p>\n<p>As expected, Innovative's second quarter showed another great performance, and its stock is up 10% since those results were released Aug. 5. In the quarter ended June 30, total revenue jumped 101% year over year to $49 million. (The company's main source of income is rental income paid by the cannabis companies.) Rising revenue also brought in another quarter of profits. Net income grew to $29 million from $13 million in the year-ago period, and adjusted funds from operations, or AFFO, surged by 105% to $43 million for the quarter. </p>\n<p>For a REIT, AFFO plays the same role as net earnings do for a non-REIT, showing how much cash is available to be paid to shareholders as dividends. Rising AFFO is a good sign, meaning a business (in this case, Innovative) is capable of consistently paying dividends. The company paid a quarterly dividend of $1.40 per share on July 15, which was an increase of 6% from the first quarter and a 32% hike from the year-ago period. It marked the 11th dividend increase since its initial public offering in 2016. </p>\n<p>Currently, the company owns 73 properties in 18 states totaling 6.8 million square feet of space; 100% of its properties are leased out by cannabis companies. Between April 1 and Aug. 4, the company made five acquisitions of new properties and three lease amendments for existing properties.&nbsp;Some of its tenants include popular cannabis players <b>Cresco Labs, Trulieve Cannabis</b>,&nbsp;<b>Curaleaf Holdings</b>, and&nbsp;<b><a href=\"https://laohu8.com/S/GNBC\">Green</a> Thumb Industries</b>. These companies' expansion plans, and ever-expanding state legalization, lead me to believe Innovative will continue to grow.&nbsp;</p>\n<p>If you want to create wealth by investing, you need to keep a long time frame in mind. Growth stocks need time to show their full potential, especially in a nascent industry like marijuana. Both Trulieve and Innovative have strong financials and can flourish as the industry expands. Risk-averse investors can start with a small investment in these high-growth pot stocks that have the potential to double their money five to 10 years down the line.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 No-Brainer Stocks to Buy in the Cannabis Sector</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 No-Brainer Stocks to Buy in the Cannabis Sector\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/20/2-no-brainer-stocks-to-buy-in-cannabis-sector/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With state cannabis legalization ramping up across the U.S. and chances of federal legalization improving, investors might not want to lose out on this evolving sector. And outstanding second-quarter ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/20/2-no-brainer-stocks-to-buy-in-cannabis-sector/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IIPR":"Innovative Industrial Properties Inc","TCNNF":"Trulieve Cannabis Corporation"},"source_url":"https://www.fool.com/investing/2021/08/20/2-no-brainer-stocks-to-buy-in-cannabis-sector/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160710591","content_text":"With state cannabis legalization ramping up across the U.S. and chances of federal legalization improving, investors might not want to lose out on this evolving sector. And outstanding second-quarter earnings from these two pot stocks in particular are excellent examples of the sector's high growth and exciting upside.\nFlorida-based Trulieve Cannabis Corporation (OTC: TCNNF) reported another great quarter with outstanding revenue growth and positive earnings before interest, tax, depreciation, and amortization (EBITDA). Meanwhile, marijuana REIT Innovative Industrial Properties Inc (NYSE: IIPR) not only grew revenue, but also profits. Both are profitable companies expanding at a rapid rate to capture the cannabis market in the U.S. Let's dig into their second-quarter results and determine why they could be the best fit for your portfolio.\n\nImage source: Getty Images.\nTrulieve Cannabis' Q2 turned out even better than Q1\nThe credit for Trulieve's consistent performance mostly goes to its dominance in its home state, where it operates 85 stores. Its total revenue grew 78% year over year to $215 million. Adjusted EBITDA came in at $95 million, a 55% jump from the prior-year quarter. The company also generated net profits of $41 million, a 116% year-over-year increase. Q2 marks the company's 14th consecutive quarter of profitability, which is impressive considering how its Canadian counterparts are struggling to generate profits. \nFor the six months ended June 30, the company has reached $409 million in revenue. If it continues to grow at this rate, I wouldn't be surprised if it ends 2021 with more than $1 billion. Note that these numbers don't include the revenue generated from the Harvest Health & Recreation acquisition (once it completes), so expect them to climb even higher. Trulieve's purchase of Arizona-based Harvest Health in May pushed its store count to a total of 140, and it now boasts 3 million square feet of cultivation capacity in the U.S. The move also gives Trulieve access to markets in Arizona (which recently legalized recreational cannabis), Pennsylvania, and Maryland.\nInitially, investors were concerned with Trulieve's focus only on the Florida market; I was too. But a smart company knows to strengthen its roots first and then focus on expanding, and I applaud Trulieve for doing just that. The company used its capital resources well and continued generating profits first, without going on an acquisition spree. This made room for the Harvest acquisition to bolster Trulieve's presence in key cannabis markets across the nation. The company had cash and cash equivalents of $289 million and net debt of $118 million at the end of Q2. \nThe only concern I have is that most of its revenue generated during the quarter came from the sale of medical cannabis products (all that's currently legal in Florida). Trulieve will need to add focus on recreational revenue going forward. Markets in New York, Arizona, and New Jersey (which recently legalized recreational marijuana) present a tremendous opportunity for U.S. cannabis companies, but Trulieve has no stores in any of these states yet. \nAnalysts expect a 132% upside for Trulieve's stock in the next 12 months, which I think is possible looking at the rate the company is growing. \nThis REIT's stock popped after another strong quarter\nInnovative Industrial Properties is not directly linked to cannabis, but management has taken good advantage of the marijuana boom in the U.S. Its business model, in which it acquires properties from medical cannabis companies and leases them back to the sellers, has worked wonders for both parties; because cannabis is illegal at the federal level in the U.S., access to capital can be hard for marijuana companies to find in other ways. Besides allowing investors indirect access to the industry, Innovative is also a real estate investment trust (or REIT), meaning it is mandated by law to pay 90% of its taxable income as dividends. \nAs expected, Innovative's second quarter showed another great performance, and its stock is up 10% since those results were released Aug. 5. In the quarter ended June 30, total revenue jumped 101% year over year to $49 million. (The company's main source of income is rental income paid by the cannabis companies.) Rising revenue also brought in another quarter of profits. Net income grew to $29 million from $13 million in the year-ago period, and adjusted funds from operations, or AFFO, surged by 105% to $43 million for the quarter. \nFor a REIT, AFFO plays the same role as net earnings do for a non-REIT, showing how much cash is available to be paid to shareholders as dividends. Rising AFFO is a good sign, meaning a business (in this case, Innovative) is capable of consistently paying dividends. The company paid a quarterly dividend of $1.40 per share on July 15, which was an increase of 6% from the first quarter and a 32% hike from the year-ago period. It marked the 11th dividend increase since its initial public offering in 2016. \nCurrently, the company owns 73 properties in 18 states totaling 6.8 million square feet of space; 100% of its properties are leased out by cannabis companies. Between April 1 and Aug. 4, the company made five acquisitions of new properties and three lease amendments for existing properties. Some of its tenants include popular cannabis players Cresco Labs, Trulieve Cannabis, Curaleaf Holdings, and Green Thumb Industries. These companies' expansion plans, and ever-expanding state legalization, lead me to believe Innovative will continue to grow. \nIf you want to create wealth by investing, you need to keep a long time frame in mind. Growth stocks need time to show their full potential, especially in a nascent industry like marijuana. Both Trulieve and Innovative have strong financials and can flourish as the industry expands. Risk-averse investors can start with a small investment in these high-growth pot stocks that have the potential to double their money five to 10 years down the line.","news_type":1},"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":819412201,"gmtCreate":1630086512203,"gmtModify":1676530221959,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when bitcoin rise back to $60k????","listText":"when bitcoin rise back to $60k????","text":"when bitcoin rise back to $60k????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/819412201","repostId":"1199074003","repostType":4,"repost":{"id":"1199074003","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630077382,"share":"https://ttm.financial/m/news/1199074003?lang=&edition=full_marsco","pubTime":"2021-08-27 23:16","market":"us","language":"en","title":"Crypto stocks surged in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199074003","media":"Tiger Newspress","summary":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,","content":"<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks surged in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks surged in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-27 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SOS":"SOS Limited","RIOT":"Riot Platforms","NCTY":"第九城市","COIN":"Coinbase Global, Inc.","EBON":"亿邦国际","BTBT":"Bit Digital, Inc.","MARA":"MARA Holdings","BTCM":"BIT Mining","CAN":"嘉楠科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199074003","content_text":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase and Paypal climbed between 1% and 13%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":584,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581978054709801","authorId":"3581978054709801","name":"Nickystonks","avatar":"https://static.tigerbbs.com/9ea10f153b0e264f05c7d19fcc08cdee","crmLevel":3,"crmLevelSwitch":0,"idStr":"3581978054709801","authorIdStr":"3581978054709801"},"content":"maybe. 50k is a resistance level. let's see if it breaks it","text":"maybe. 50k is a resistance level. let's see if it breaks it","html":"maybe. 50k is a resistance level. let's see if it breaks it"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886336965,"gmtCreate":1631549461457,"gmtModify":1676530574165,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"ford should be a $15 share..i wish","listText":"ford should be a $15 share..i wish","text":"ford should be a $15 share..i wish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/886336965","repostId":"2167658404","repostType":2,"isVote":1,"tweetType":1,"viewCount":1292,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3586655655659820","authorId":"3586655655659820","name":"sunshine138","avatar":"https://static.tigerbbs.com/23149c63a63bfeec1572cc27e1322750","crmLevel":3,"crmLevelSwitch":0,"idStr":"3586655655659820","authorIdStr":"3586655655659820"},"content":"When will it move there","text":"When will it move there","html":"When will it move there"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814358162,"gmtCreate":1630768928456,"gmtModify":1676530392740,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>hope to reach half Tesla price haha","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>hope to reach half Tesla price haha","text":"$NIO Inc.(NIO)$hope to reach half Tesla price haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/814358162","isVote":1,"tweetType":1,"viewCount":1467,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":1,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"content":"Nio to the moon??????","text":"Nio to the moon??????","html":"Nio to the moon??????"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863229400,"gmtCreate":1632400374400,"gmtModify":1676530772716,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Pfizer can reach $50 by Oct....i wish","listText":"Pfizer can reach $50 by Oct....i wish","text":"Pfizer can reach $50 by Oct....i wish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/863229400","repostId":"1133566174","repostType":4,"repost":{"id":"1133566174","kind":"news","pubTimestamp":1632397453,"share":"https://ttm.financial/m/news/1133566174?lang=&edition=full_marsco","pubTime":"2021-09-23 19:44","market":"us","language":"en","title":"Despite Vaccine Uncertainty, Pfizer Is a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1133566174","media":"InvestorPlace","summary":"Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a compan","content":"<blockquote>\n <b>Forget the booster shot controversy, PFE stock has better days ahead.</b>\n</blockquote>\n<p>What would happen if a company developed a massive new product and no <a href=\"https://laohu8.com/S/AONE.U\">one</a> cared? For&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>’s</b> investors, that has been the question for the past year. Despite coming up with a blockbuster vaccine for the novel coronavirus, PFE stock did basically nothing for an extended period.</p>\n<p>That finally changed this summer, when Pfizer belatedly rallied to new all-time highs. Now though, the gains are fading almost as quickly as they happened. In its <a href=\"https://laohu8.com/S/QTWO\">Q2</a> earnings release, Pfizer reported 93% year-over-year revenue growth. Yet shares are up less than 20% over the past 12 months. Why have investors not given Pfizer credit for its performance, and will that change in the future?</p>\n<p><b>Vaccine Hits A Setback</b></p>\n<p>Pfizer has enjoyed incredible revenue growth over the past year due to its Covid-19 vaccine. The majority of vaccinated <a href=\"https://laohu8.com/S/AFG\">American</a> adults have taken the Pfizer vaccine, and it’s had strong sales overseas as well.</p>\n<p>Despite that, however, PFE stock didn’t move too much. At least, not until July of this year. At that time, PFE stock finally took off. The reason why is that investors started to price in the expectation that people would need to take vaccine booster shots to maintain efficacy.</p>\n<p>The idea of a third, and potentially even fourth or more dose of vaccines would have created a far more enduring revenue boost for Pfizer. Up until recently, investors had shied away from Pfizer despite its massive top-line growth because they anticipated that the Covid business would quickly recede. With booster shots, however, the vaccine would have taken on another level of importance to the company.</p>\n<p>This scenario is now under increasing doubt, however. A Food and Drug Administration (FDA) advisory panel recentlyrecommended againstadvising booster shots of the Pfizer vaccine. A large majority of the panelists voted that the data on hand was insufficient to warrant booster shots. That comes amid reports that&nbsp;<b>Moderna’s</b>(NASDAQ:<b><u>MRNA</u></b>) vaccine remains effective in a higher percentage of people than Pfizer’s after 120 days.</p>\n<p>This is hardly the final word on booster shots or the efficacy of Moderna versus Pfizer. Pfizer’s investors shouldn’t discount the possibility that the FDA later comes around on additional rounds of the vaccine. For now, however, the prospects are looking more uncertain.</p>\n<p><b>Baseline Valuation Is Not That Demanding</b></p>\n<p>Let’s go back in time to 2019 and pretend that we’ve never heard of the pandemic. What does an investment in Pfizer look like in this hypothetical scenario? For full-year 2018, Pfizer generated $1.87 of EPS. In 2019, this leapt to $2.87.</p>\n<p>Based on today’s stock price just below $44, PFE stock is selling at 23x 2018 earnings or 15x 2019 earnings. With no benefit from the current Covid-19 vaccine whatsoever, Pfizer stock would still be going for a reasonable multiple.</p>\n<p>Yes, you can argue that pharmaceutical companies should trade for lower P/E multiples than many other industries given the high cost of drug development and quick patent expiries. Still, with earnings as strong as they were in 2018-19, it’s not hard to get behind the stock at $44 even if you give the company zero credit for the Covid-19 vaccine. Forget about booster shots for a minute, traders are pricing Pfizer like there will be little more revenue from the vaccine whatsoever.</p>\n<p><b>PFE Stock Verdict</b></p>\n<p>Right now, Pfizer stock is inextricably linked to its vaccine’s outlook. When there is positive news on that front, PFE stock surges. When there is a setback, PFE stock sells off hard. That’s a totally understandable market reaction. Many traders are trained to react quickly to the latest headline.</p>\n<p>For longer-term investors, however, Pfizer is an opportunity regardless of the trajectory of the vaccine. Even if boosters ultimately aren’t a big thing, Pfizer can still make investors money from this entry point.</p>\n<p>The company is a tremendous diversified pharmaceutical giant. It was in good shape long before the pandemic, and it has dozens of promising drugs in its pipeline to power it for the next decade and beyond. The company is reaping a windfall right now, but it’s not like that’s its only iron in the fire.</p>\n<p>If the Covid-19 business continues longer than forecast, that’s all upside to the stock price. However, from this starting point, there’s sufficient margin of safety to support a purchase in most possible outcomes.</p>\n<p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Despite Vaccine Uncertainty, Pfizer Is a Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDespite Vaccine Uncertainty, Pfizer Is a Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-23 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the ...</p>\n\n<a href=\"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133566174","content_text":"Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the question for the past year. Despite coming up with a blockbuster vaccine for the novel coronavirus, PFE stock did basically nothing for an extended period.\nThat finally changed this summer, when Pfizer belatedly rallied to new all-time highs. Now though, the gains are fading almost as quickly as they happened. In its Q2 earnings release, Pfizer reported 93% year-over-year revenue growth. Yet shares are up less than 20% over the past 12 months. Why have investors not given Pfizer credit for its performance, and will that change in the future?\nVaccine Hits A Setback\nPfizer has enjoyed incredible revenue growth over the past year due to its Covid-19 vaccine. The majority of vaccinated American adults have taken the Pfizer vaccine, and it’s had strong sales overseas as well.\nDespite that, however, PFE stock didn’t move too much. At least, not until July of this year. At that time, PFE stock finally took off. The reason why is that investors started to price in the expectation that people would need to take vaccine booster shots to maintain efficacy.\nThe idea of a third, and potentially even fourth or more dose of vaccines would have created a far more enduring revenue boost for Pfizer. Up until recently, investors had shied away from Pfizer despite its massive top-line growth because they anticipated that the Covid business would quickly recede. With booster shots, however, the vaccine would have taken on another level of importance to the company.\nThis scenario is now under increasing doubt, however. A Food and Drug Administration (FDA) advisory panel recentlyrecommended againstadvising booster shots of the Pfizer vaccine. A large majority of the panelists voted that the data on hand was insufficient to warrant booster shots. That comes amid reports that Moderna’s(NASDAQ:MRNA) vaccine remains effective in a higher percentage of people than Pfizer’s after 120 days.\nThis is hardly the final word on booster shots or the efficacy of Moderna versus Pfizer. Pfizer’s investors shouldn’t discount the possibility that the FDA later comes around on additional rounds of the vaccine. For now, however, the prospects are looking more uncertain.\nBaseline Valuation Is Not That Demanding\nLet’s go back in time to 2019 and pretend that we’ve never heard of the pandemic. What does an investment in Pfizer look like in this hypothetical scenario? For full-year 2018, Pfizer generated $1.87 of EPS. In 2019, this leapt to $2.87.\nBased on today’s stock price just below $44, PFE stock is selling at 23x 2018 earnings or 15x 2019 earnings. With no benefit from the current Covid-19 vaccine whatsoever, Pfizer stock would still be going for a reasonable multiple.\nYes, you can argue that pharmaceutical companies should trade for lower P/E multiples than many other industries given the high cost of drug development and quick patent expiries. Still, with earnings as strong as they were in 2018-19, it’s not hard to get behind the stock at $44 even if you give the company zero credit for the Covid-19 vaccine. Forget about booster shots for a minute, traders are pricing Pfizer like there will be little more revenue from the vaccine whatsoever.\nPFE Stock Verdict\nRight now, Pfizer stock is inextricably linked to its vaccine’s outlook. When there is positive news on that front, PFE stock surges. When there is a setback, PFE stock sells off hard. That’s a totally understandable market reaction. Many traders are trained to react quickly to the latest headline.\nFor longer-term investors, however, Pfizer is an opportunity regardless of the trajectory of the vaccine. Even if boosters ultimately aren’t a big thing, Pfizer can still make investors money from this entry point.\nThe company is a tremendous diversified pharmaceutical giant. It was in good shape long before the pandemic, and it has dozens of promising drugs in its pipeline to power it for the next decade and beyond. The company is reaping a windfall right now, but it’s not like that’s its only iron in the fire.\nIf the Covid-19 business continues longer than forecast, that’s all upside to the stock price. However, from this starting point, there’s sufficient margin of safety to support a purchase in most possible outcomes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1272,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4092216435500580","authorId":"4092216435500580","name":"SimonSim","avatar":"https://static.tigerbbs.com/f2870d5ab54ba75f2d74ad8cb044473a","crmLevel":2,"crmLevelSwitch":0,"idStr":"4092216435500580","authorIdStr":"4092216435500580"},"content":"[Happy] [Happy] [Happy]","text":"[Happy] [Happy] [Happy]","html":"[Happy] [Happy] [Happy]"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869784588,"gmtCreate":1632322282944,"gmtModify":1676530752993,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Maybe&nbsp;Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","listText":"Maybe&nbsp;Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","text":"Maybe Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/869784588","repostId":"1143821004","repostType":4,"isVote":1,"tweetType":1,"viewCount":1283,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3580536610076415","authorId":"3580536610076415","name":"BettyT","avatar":"https://static.tigerbbs.com/6a4dfe2f455acd2af7629f83ce30e20c","crmLevel":5,"crmLevelSwitch":0,"idStr":"3580536610076415","authorIdStr":"3580536610076415"},"content":"diversified ? Haha ??","text":"diversified ? Haha ??","html":"diversified ? Haha ??"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819418625,"gmtCreate":1630086116667,"gmtModify":1676530221910,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when nio xpeng rise to$50???","listText":"when nio xpeng rise to$50???","text":"when nio xpeng rise to$50???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/819418625","repostId":"2162021329","repostType":4,"repost":{"id":"2162021329","kind":"highlight","pubTimestamp":1630076362,"share":"https://ttm.financial/m/news/2162021329?lang=&edition=full_marsco","pubTime":"2021-08-27 22:59","market":"us","language":"en","title":"Why Lordstown Motors Stock Has Surged This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2162021329","media":"Motley Fool","summary":"And why investors should temper their enthusiasm.","content":"<h2>What happened</h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/RIDE\">Lordstown Motors Corp.</a> </b>(NASDAQ:RIDE) surged 24.1% this week through Thursday, following news that the embattled electric truck start-up has hired a new CEO with deep auto industry experience.</p>\n<p>That's encouraging news for investors who have watched the stock decline sharply in recent months. But while the new CEO has a solid resume, the company faces a daunting road to delivering on investors' expectations.</p>\n<h2>So what</h2>\n<p>Lordstown said on Thursday that it has a new CEO: Daniel Ninivaggi is the former CEO of investor Carl Icahn's automotive holdings, and earlier held executive roles at Tier 1 auto suppliers <b>Lear</b>&nbsp;and Federal Mogul (now part of <b>Tenneco</b>).&nbsp;</p>\n<p>Ninivaggi will need all his experience to get Lordstown on track. The company has been reeling since the abrupt departure of its founder and its chief financial officer in June, following an investigation into allegations that they greatly exaggerated customer interest in Lordstown's upcoming electric Endurance pickup.&nbsp;</p>\n<p>Now, Lordstown is short on cash and short on potential sources of new cash, just as it appears to have lost its first-mover advantage to commercial-vehicle market leader <b>Ford Motor Company</b>. (Investors hoping that Ninivaggi might bring a big investment from Icahn should note Ninivaggi parted ways with Icahn's organization in 2019.)&nbsp;</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F640972%2Flordstown-endurance-pickup-1.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Lordstown's truck is behind schedule and buyers don't appear to be lining up. Can new CEO Ninivaggi turn things around? Image source: Lordstown Motors.</p>\n<p>But that said, the arrival of Ninivaggi is good news, and I think investors were right to be cheered this week.</p>\n<h2>Now what</h2>\n<p>Ninivaggi can almost certainly help address Lordstown's urgent needs right away, at least to some extent. His resume brings the kind of credibility that can open doors with potential investors and other automotive heavyweights.&nbsp;</p>\n<p>But investors shouldn't underestimate the difficulties here, even with Ninivaggi steering the shop. Simply put, Lordstown needs to be able to establish a beachhead in the super competitive commercial vehicle market to survive -- and now that giant Ford has thrown down a gauntlet with its impressive F-150 Lightning, that will be a big, big challenge.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Lordstown Motors Stock Has Surged This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Lordstown Motors Stock Has Surged This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 22:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/27/why-lordstown-motors-stock-has-surged-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Lordstown Motors Corp. (NASDAQ:RIDE) surged 24.1% this week through Thursday, following news that the embattled electric truck start-up has hired a new CEO with deep auto ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/27/why-lordstown-motors-stock-has-surged-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/08/27/why-lordstown-motors-stock-has-surged-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162021329","content_text":"What happened\nShares of Lordstown Motors Corp. (NASDAQ:RIDE) surged 24.1% this week through Thursday, following news that the embattled electric truck start-up has hired a new CEO with deep auto industry experience.\nThat's encouraging news for investors who have watched the stock decline sharply in recent months. But while the new CEO has a solid resume, the company faces a daunting road to delivering on investors' expectations.\nSo what\nLordstown said on Thursday that it has a new CEO: Daniel Ninivaggi is the former CEO of investor Carl Icahn's automotive holdings, and earlier held executive roles at Tier 1 auto suppliers Lear and Federal Mogul (now part of Tenneco). \nNinivaggi will need all his experience to get Lordstown on track. The company has been reeling since the abrupt departure of its founder and its chief financial officer in June, following an investigation into allegations that they greatly exaggerated customer interest in Lordstown's upcoming electric Endurance pickup. \nNow, Lordstown is short on cash and short on potential sources of new cash, just as it appears to have lost its first-mover advantage to commercial-vehicle market leader Ford Motor Company. (Investors hoping that Ninivaggi might bring a big investment from Icahn should note Ninivaggi parted ways with Icahn's organization in 2019.) \n\nLordstown's truck is behind schedule and buyers don't appear to be lining up. Can new CEO Ninivaggi turn things around? Image source: Lordstown Motors.\nBut that said, the arrival of Ninivaggi is good news, and I think investors were right to be cheered this week.\nNow what\nNinivaggi can almost certainly help address Lordstown's urgent needs right away, at least to some extent. His resume brings the kind of credibility that can open doors with potential investors and other automotive heavyweights. \nBut investors shouldn't underestimate the difficulties here, even with Ninivaggi steering the shop. Simply put, Lordstown needs to be able to establish a beachhead in the super competitive commercial vehicle market to survive -- and now that giant Ford has thrown down a gauntlet with its impressive F-150 Lightning, that will be a big, big challenge.","news_type":1},"isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818294685,"gmtCreate":1630411172447,"gmtModify":1676530295627,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Alibaba or Sea Ltd reach $500 first??","listText":"Alibaba or Sea Ltd reach $500 first??","text":"Alibaba or Sea Ltd reach $500 first??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818294685","repostId":"2163859671","repostType":4,"isVote":1,"tweetType":1,"viewCount":979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863228838,"gmtCreate":1632400543624,"gmtModify":1676530772779,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Nio niu (bull)ah!","listText":"Nio niu (bull)ah!","text":"Nio niu (bull)ah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/863228838","repostId":"1135139549","repostType":4,"isVote":1,"tweetType":1,"viewCount":1268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836602761,"gmtCreate":1629473057753,"gmtModify":1676530054050,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when sundial rises????","listText":"when sundial rises????","text":"when sundial rises????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/836602761","repostId":"2160710591","repostType":4,"repost":{"id":"2160710591","kind":"highlight","pubTimestamp":1629470661,"share":"https://ttm.financial/m/news/2160710591?lang=&edition=full_marsco","pubTime":"2021-08-20 22:44","market":"us","language":"en","title":"2 No-Brainer Stocks to Buy in the Cannabis Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2160710591","media":"Motley Fool","summary":"A multi-state operator and an unconventional pot stock are both hot buys after reporting second-quarter earnings.","content":"<p>With state cannabis legalization ramping up across the U.S. and chances of federal legalization improving, investors might not want to lose out on this evolving sector. And outstanding second-quarter earnings from these two pot stocks in particular are excellent examples of the sector's high growth and exciting upside.</p>\n<p>Florida-based&nbsp;<b><a href=\"https://laohu8.com/S/TCNNF\">Trulieve Cannabis Corporation</a> </b>(OTC:&nbsp;TCNNF)<b>&nbsp;</b>reported another great quarter with outstanding revenue growth and positive earnings before interest, tax, depreciation, and amortization (EBITDA). Meanwhile, marijuana REIT<b> <a href=\"https://laohu8.com/S/IIPR\">Innovative Industrial Properties Inc</a> </b>(NYSE:&nbsp;IIPR) not only grew revenue, but also profits. Both are profitable companies expanding at a rapid rate to capture the cannabis market in the U.S. Let's dig into their second-quarter results and determine why they could be the best fit for your portfolio.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F639496%2Fpiggy-bank.jpeg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty&nbsp;Images.</p>\n<h2>Trulieve Cannabis' Q2 turned out even better than Q1</h2>\n<p>The credit for Trulieve's consistent performance mostly goes to its dominance in its home state, where it operates 85 stores. Its total revenue grew 78% year over year to $215 million. Adjusted EBITDA came in at $95 million, a 55% jump from the prior-year quarter. The company also generated net profits of $41 million, a 116% year-over-year increase. Q2 marks the company's 14th consecutive quarter of profitability, which is impressive considering how its Canadian counterparts are struggling to generate profits. </p>\n<p>For the six months ended June 30, the company has reached $409 million in revenue. If it continues to grow at this rate, I wouldn't be surprised if it ends 2021 with more than $1 billion. Note that these numbers don't include the revenue generated from the <b>Harvest Health &amp; Recreation&nbsp;</b>acquisition (once it completes), so expect them to climb even higher. Trulieve's purchase of Arizona-based Harvest Health in May pushed its store count to a total of 140, and it now boasts 3 million square feet of cultivation capacity in the U.S. The move also gives Trulieve access to markets in Arizona (which recently legalized recreational cannabis), Pennsylvania, and Maryland.</p>\n<p>Initially, investors were concerned with Trulieve's focus only on the Florida market; I was too. But a smart company knows to strengthen its roots first and then focus on expanding, and I applaud Trulieve for doing just that. The company used its capital resources well and continued generating profits first, without going on an acquisition spree. This made room for the Harvest acquisition to bolster Trulieve's presence in key cannabis markets across the nation. The company had cash and cash equivalents of $289 million and net debt of $118 million at the end of Q2. </p>\n<p>The only concern I have is that most of its revenue generated during the quarter came from the sale of medical cannabis products (all that's currently legal in Florida). Trulieve will need to add focus on recreational revenue going forward. Markets in <a href=\"https://laohu8.com/S/NWY\">New York</a>, Arizona, and New Jersey (which recently legalized recreational marijuana) present a tremendous opportunity for U.S. cannabis companies, but Trulieve has no stores in any of these states yet. </p>\n<p>Analysts expect a 132% upside for Trulieve's stock in the next 12 months, which I think is possible looking at the rate the company is growing. </p>\n<h2>This REIT's stock popped after another strong quarter</h2>\n<p>Innovative Industrial Properties is not directly linked to cannabis, but management has taken good advantage of the marijuana boom in the U.S. Its business model, in which it acquires properties from medical cannabis companies and leases them back to the sellers, has worked wonders for both parties; because cannabis is illegal at the federal level in the U.S., access to capital can be hard for marijuana companies to find in other ways. Besides allowing investors indirect access to the industry, Innovative is also a real estate investment trust (or REIT), meaning it is mandated by law to pay 90% of its taxable income as dividends.&nbsp;</p>\n<p>As expected, Innovative's second quarter showed another great performance, and its stock is up 10% since those results were released Aug. 5. In the quarter ended June 30, total revenue jumped 101% year over year to $49 million. (The company's main source of income is rental income paid by the cannabis companies.) Rising revenue also brought in another quarter of profits. Net income grew to $29 million from $13 million in the year-ago period, and adjusted funds from operations, or AFFO, surged by 105% to $43 million for the quarter. </p>\n<p>For a REIT, AFFO plays the same role as net earnings do for a non-REIT, showing how much cash is available to be paid to shareholders as dividends. Rising AFFO is a good sign, meaning a business (in this case, Innovative) is capable of consistently paying dividends. The company paid a quarterly dividend of $1.40 per share on July 15, which was an increase of 6% from the first quarter and a 32% hike from the year-ago period. It marked the 11th dividend increase since its initial public offering in 2016. </p>\n<p>Currently, the company owns 73 properties in 18 states totaling 6.8 million square feet of space; 100% of its properties are leased out by cannabis companies. Between April 1 and Aug. 4, the company made five acquisitions of new properties and three lease amendments for existing properties.&nbsp;Some of its tenants include popular cannabis players <b>Cresco Labs, Trulieve Cannabis</b>,&nbsp;<b>Curaleaf Holdings</b>, and&nbsp;<b><a href=\"https://laohu8.com/S/GNBC\">Green</a> Thumb Industries</b>. These companies' expansion plans, and ever-expanding state legalization, lead me to believe Innovative will continue to grow.&nbsp;</p>\n<p>If you want to create wealth by investing, you need to keep a long time frame in mind. Growth stocks need time to show their full potential, especially in a nascent industry like marijuana. Both Trulieve and Innovative have strong financials and can flourish as the industry expands. Risk-averse investors can start with a small investment in these high-growth pot stocks that have the potential to double their money five to 10 years down the line.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 No-Brainer Stocks to Buy in the Cannabis Sector</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 No-Brainer Stocks to Buy in the Cannabis Sector\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/20/2-no-brainer-stocks-to-buy-in-cannabis-sector/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With state cannabis legalization ramping up across the U.S. and chances of federal legalization improving, investors might not want to lose out on this evolving sector. And outstanding second-quarter ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/20/2-no-brainer-stocks-to-buy-in-cannabis-sector/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IIPR":"Innovative Industrial Properties Inc","TCNNF":"Trulieve Cannabis Corporation"},"source_url":"https://www.fool.com/investing/2021/08/20/2-no-brainer-stocks-to-buy-in-cannabis-sector/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160710591","content_text":"With state cannabis legalization ramping up across the U.S. and chances of federal legalization improving, investors might not want to lose out on this evolving sector. And outstanding second-quarter earnings from these two pot stocks in particular are excellent examples of the sector's high growth and exciting upside.\nFlorida-based Trulieve Cannabis Corporation (OTC: TCNNF) reported another great quarter with outstanding revenue growth and positive earnings before interest, tax, depreciation, and amortization (EBITDA). Meanwhile, marijuana REIT Innovative Industrial Properties Inc (NYSE: IIPR) not only grew revenue, but also profits. Both are profitable companies expanding at a rapid rate to capture the cannabis market in the U.S. Let's dig into their second-quarter results and determine why they could be the best fit for your portfolio.\n\nImage source: Getty Images.\nTrulieve Cannabis' Q2 turned out even better than Q1\nThe credit for Trulieve's consistent performance mostly goes to its dominance in its home state, where it operates 85 stores. Its total revenue grew 78% year over year to $215 million. Adjusted EBITDA came in at $95 million, a 55% jump from the prior-year quarter. The company also generated net profits of $41 million, a 116% year-over-year increase. Q2 marks the company's 14th consecutive quarter of profitability, which is impressive considering how its Canadian counterparts are struggling to generate profits. \nFor the six months ended June 30, the company has reached $409 million in revenue. If it continues to grow at this rate, I wouldn't be surprised if it ends 2021 with more than $1 billion. Note that these numbers don't include the revenue generated from the Harvest Health & Recreation acquisition (once it completes), so expect them to climb even higher. Trulieve's purchase of Arizona-based Harvest Health in May pushed its store count to a total of 140, and it now boasts 3 million square feet of cultivation capacity in the U.S. The move also gives Trulieve access to markets in Arizona (which recently legalized recreational cannabis), Pennsylvania, and Maryland.\nInitially, investors were concerned with Trulieve's focus only on the Florida market; I was too. But a smart company knows to strengthen its roots first and then focus on expanding, and I applaud Trulieve for doing just that. The company used its capital resources well and continued generating profits first, without going on an acquisition spree. This made room for the Harvest acquisition to bolster Trulieve's presence in key cannabis markets across the nation. The company had cash and cash equivalents of $289 million and net debt of $118 million at the end of Q2. \nThe only concern I have is that most of its revenue generated during the quarter came from the sale of medical cannabis products (all that's currently legal in Florida). Trulieve will need to add focus on recreational revenue going forward. Markets in New York, Arizona, and New Jersey (which recently legalized recreational marijuana) present a tremendous opportunity for U.S. cannabis companies, but Trulieve has no stores in any of these states yet. \nAnalysts expect a 132% upside for Trulieve's stock in the next 12 months, which I think is possible looking at the rate the company is growing. \nThis REIT's stock popped after another strong quarter\nInnovative Industrial Properties is not directly linked to cannabis, but management has taken good advantage of the marijuana boom in the U.S. Its business model, in which it acquires properties from medical cannabis companies and leases them back to the sellers, has worked wonders for both parties; because cannabis is illegal at the federal level in the U.S., access to capital can be hard for marijuana companies to find in other ways. Besides allowing investors indirect access to the industry, Innovative is also a real estate investment trust (or REIT), meaning it is mandated by law to pay 90% of its taxable income as dividends. \nAs expected, Innovative's second quarter showed another great performance, and its stock is up 10% since those results were released Aug. 5. In the quarter ended June 30, total revenue jumped 101% year over year to $49 million. (The company's main source of income is rental income paid by the cannabis companies.) Rising revenue also brought in another quarter of profits. Net income grew to $29 million from $13 million in the year-ago period, and adjusted funds from operations, or AFFO, surged by 105% to $43 million for the quarter. \nFor a REIT, AFFO plays the same role as net earnings do for a non-REIT, showing how much cash is available to be paid to shareholders as dividends. Rising AFFO is a good sign, meaning a business (in this case, Innovative) is capable of consistently paying dividends. The company paid a quarterly dividend of $1.40 per share on July 15, which was an increase of 6% from the first quarter and a 32% hike from the year-ago period. It marked the 11th dividend increase since its initial public offering in 2016. \nCurrently, the company owns 73 properties in 18 states totaling 6.8 million square feet of space; 100% of its properties are leased out by cannabis companies. Between April 1 and Aug. 4, the company made five acquisitions of new properties and three lease amendments for existing properties. Some of its tenants include popular cannabis players Cresco Labs, Trulieve Cannabis, Curaleaf Holdings, and Green Thumb Industries. These companies' expansion plans, and ever-expanding state legalization, lead me to believe Innovative will continue to grow. \nIf you want to create wealth by investing, you need to keep a long time frame in mind. Growth stocks need time to show their full potential, especially in a nascent industry like marijuana. Both Trulieve and Innovative have strong financials and can flourish as the industry expands. Risk-averse investors can start with a small investment in these high-growth pot stocks that have the potential to double their money five to 10 years down the line.","news_type":1},"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886333560,"gmtCreate":1631549154550,"gmtModify":1676530574110,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"sold first maybe buy later &lt;8,pls like n share your comments&nbsp;thanks","listText":"sold first maybe buy later &lt;8,pls like n share your comments&nbsp;thanks","text":"sold first maybe buy later <8,pls like n share your comments thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/886333560","repostId":"1126978010","repostType":4,"repost":{"id":"1126978010","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631544701,"share":"https://ttm.financial/m/news/1126978010?lang=&edition=full_marsco","pubTime":"2021-09-13 22:51","market":"us","language":"en","title":"Ocugen shares surged more than 13% in Monday morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126978010","media":"Tiger Newspress","summary":"Ocugen shares surged more than 13% in Monday morning trading.\n\nVarious companies have been engaged i","content":"<p>Ocugen shares surged more than 13%&nbsp;in Monday morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/8fcba6c91ee88af0dd90608a79065282\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Various companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.</p>\n<p>Clinical-stage biotech firm Ocugen (<b>OCGN</b>) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.</p>\n<p>The announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of&nbsp;$18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.</p>\n<p>As rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.</p>\n<p>However, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.</p>\n<p><b>Delta Variant Concerns Pushing OCGN Stock up</b></p>\n<p>Newly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.</p>\n<p>This new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.</p>\n<p>According to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.</p>\n<p><b>Short-term Catalyst behind the Sudden Spike</b></p>\n<p>Ocugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.</p>\n<p>Health Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.</p>\n<p>Moreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.</p>\n<p><b>Ocugen Needs to Progress</b></p>\n<p>The biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.</p>\n<p>On top of that, it posted a&nbsp;net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.</p>\n<p>As of June 30, cash and cash equivalents stood at $115.6 million.</p>\n<p><b>Wall Street’s Take</b></p>\n<p>As per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.</p>\n<p>The&nbsp;average OCGN price target&nbsp;is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.</p>\n<p><img src=\"https://static.tigerbbs.com/9c696ea686fdeaa8d6550e1282efebf7\" tg-width=\"1099\" tg-height=\"374\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Bottom Line</b></p>\n<p>Ocugen stock could very well profit from the mounting global concerns about the Delta variant.</p>\n<p>There might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.</p>\n<p>It’s an interesting play, but not without risk.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged more than 13% in Monday morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged more than 13% in Monday morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-13 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocugen shares surged more than 13%&nbsp;in Monday morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/8fcba6c91ee88af0dd90608a79065282\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Various companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.</p>\n<p>Clinical-stage biotech firm Ocugen (<b>OCGN</b>) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.</p>\n<p>The announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of&nbsp;$18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.</p>\n<p>As rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.</p>\n<p>However, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.</p>\n<p><b>Delta Variant Concerns Pushing OCGN Stock up</b></p>\n<p>Newly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.</p>\n<p>This new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.</p>\n<p>According to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.</p>\n<p><b>Short-term Catalyst behind the Sudden Spike</b></p>\n<p>Ocugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.</p>\n<p>Health Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.</p>\n<p>Moreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.</p>\n<p><b>Ocugen Needs to Progress</b></p>\n<p>The biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.</p>\n<p>On top of that, it posted a&nbsp;net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.</p>\n<p>As of June 30, cash and cash equivalents stood at $115.6 million.</p>\n<p><b>Wall Street’s Take</b></p>\n<p>As per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.</p>\n<p>The&nbsp;average OCGN price target&nbsp;is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.</p>\n<p><img src=\"https://static.tigerbbs.com/9c696ea686fdeaa8d6550e1282efebf7\" tg-width=\"1099\" tg-height=\"374\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Bottom Line</b></p>\n<p>Ocugen stock could very well profit from the mounting global concerns about the Delta variant.</p>\n<p>There might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.</p>\n<p>It’s an interesting play, but not without risk.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126978010","content_text":"Ocugen shares surged more than 13% in Monday morning trading.\n\nVarious companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.\nClinical-stage biotech firm Ocugen (OCGN) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.\nThe announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of $18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.\nAs rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.\nHowever, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.\nDelta Variant Concerns Pushing OCGN Stock up\nNewly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.\nThis new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.\nAccording to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.\nShort-term Catalyst behind the Sudden Spike\nOcugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.\nHealth Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.\nMoreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.\nOcugen Needs to Progress\nThe biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.\nOn top of that, it posted a net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.\nAs of June 30, cash and cash equivalents stood at $115.6 million.\nWall Street’s Take\nAs per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.\nThe average OCGN price target is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.\n\nBottom Line\nOcugen stock could very well profit from the mounting global concerns about the Delta variant.\nThere might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.\nIt’s an interesting play, but not without risk.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819416733,"gmtCreate":1630086304922,"gmtModify":1676530221943,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when nio xpeng rise to $50???","listText":"when nio xpeng rise to $50???","text":"when nio xpeng rise to $50???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/819416733","repostId":"1165379113","repostType":4,"repost":{"id":"1165379113","kind":"news","pubTimestamp":1630075265,"share":"https://ttm.financial/m/news/1165379113?lang=&edition=full_marsco","pubTime":"2021-08-27 22:41","market":"us","language":"en","title":"Tesla Wants to Become an Electricity Retailer in Texas. What To Know.","url":"https://stock-news.laohu8.com/highlight/detail?id=1165379113","media":"Barrons","summary":"A Tesla subsidiary has applied to become an electricity retailer in Texas, moving to widen the energ","content":"<p>A Tesla subsidiary has applied to become an electricity retailer in Texas, moving to widen the energy ambitions of Elon Musk’s electric-vehicle company in a state with a power grid that came under scrutiny after failing in a February winter storm.</p>\n<p>Tesla Energy Ventures, a subsidiary of Tesla formed in late July, wants to sell power directly to customers as a retail electricity provider, according to an August 16 filing with the Texas Public Utility Commission.</p>\n<p>Shares in Tesla were 0.6% higher in U.S. premarket trading on Friday, outpacing a rise in futures for the&nbsp;Nasdaq 100&nbsp;index, of which Tesla is a component.</p>\n<p>Tesla also intends to build two massive utility-scale batteries to serve power companies in the state, according to Texas Monthly,which first reported the news&nbsp;on Thursday and said that the filing could be approved by November.</p>\n<p>One of those batteries would reportedly be located at a gigafactory outside Austin, where the Cybertruck and Model Y SUV are slated to be built, with another located outside Houston,based on a report from Bloomberg.</p>\n<p>Texas’ deregulated power grid includes well over 100 companies selling to consumers. The state’s power system came under the spotlight this winter, when&nbsp;a February storm&nbsp;left millions without electricity for several days.</p>\n<p>Tesla hoped to enter the Texas power market earlier, before the widespread blackouts in February, according to the Texas Monthly report.</p>\n<p>The company has a history of building utility-scale power storage, with developments in California and Australia, but becoming an electricity retailer in Texas would be a significant milestone in the expansion of Tesla’s energy division.</p>\n<p>“I can’t emphasize enough, I think long term, Tesla Energy will be of roughly the same size as Tesla Automotive,” Musk told investors last summer, after the company’s second-quarter earnings in July 2020.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Wants to Become an Electricity Retailer in Texas. What To Know.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Wants to Become an Electricity Retailer in Texas. What To Know.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 22:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-wants-to-become-an-electricity-retailer-in-texas-what-to-know-51630066304?mod=hp_DAY_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A Tesla subsidiary has applied to become an electricity retailer in Texas, moving to widen the energy ambitions of Elon Musk’s electric-vehicle company in a state with a power grid that came under ...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-wants-to-become-an-electricity-retailer-in-texas-what-to-know-51630066304?mod=hp_DAY_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-wants-to-become-an-electricity-retailer-in-texas-what-to-know-51630066304?mod=hp_DAY_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165379113","content_text":"A Tesla subsidiary has applied to become an electricity retailer in Texas, moving to widen the energy ambitions of Elon Musk’s electric-vehicle company in a state with a power grid that came under scrutiny after failing in a February winter storm.\nTesla Energy Ventures, a subsidiary of Tesla formed in late July, wants to sell power directly to customers as a retail electricity provider, according to an August 16 filing with the Texas Public Utility Commission.\nShares in Tesla were 0.6% higher in U.S. premarket trading on Friday, outpacing a rise in futures for the Nasdaq 100 index, of which Tesla is a component.\nTesla also intends to build two massive utility-scale batteries to serve power companies in the state, according to Texas Monthly,which first reported the news on Thursday and said that the filing could be approved by November.\nOne of those batteries would reportedly be located at a gigafactory outside Austin, where the Cybertruck and Model Y SUV are slated to be built, with another located outside Houston,based on a report from Bloomberg.\nTexas’ deregulated power grid includes well over 100 companies selling to consumers. The state’s power system came under the spotlight this winter, when a February storm left millions without electricity for several days.\nTesla hoped to enter the Texas power market earlier, before the widespread blackouts in February, according to the Texas Monthly report.\nThe company has a history of building utility-scale power storage, with developments in California and Australia, but becoming an electricity retailer in Texas would be a significant milestone in the expansion of Tesla’s energy division.\n“I can’t emphasize enough, I think long term, Tesla Energy will be of roughly the same size as Tesla Automotive,” Musk told investors last summer, after the company’s second-quarter earnings in July 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":449,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835513111,"gmtCreate":1629726602833,"gmtModify":1676530112928,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"pfizer up up","listText":"pfizer up up","text":"pfizer up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/835513111","repostId":"1132832038","repostType":4,"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816429803,"gmtCreate":1630515201002,"gmtModify":1676530328185,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"should&nbsp; buy sundial&nbsp;","listText":"should&nbsp; buy sundial&nbsp;","text":"should buy sundial","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816429803","repostId":"2164890060","repostType":4,"repost":{"id":"2164890060","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630508469,"share":"https://ttm.financial/m/news/2164890060?lang=&edition=full_marsco","pubTime":"2021-09-01 23:01","market":"us","language":"en","title":"U.S. pot producer Terrascend to buy rival Gage Growth for $545 mln - sources","url":"https://stock-news.laohu8.com/highlight/detail?id=2164890060","media":"Reuters","summary":"Sept 1 (Reuters) - Terrascend will buy Michigan-based rival Gage Growth Corp, backed by prominent ca","content":"<p>Sept 1 (Reuters) - Terrascend will buy Michigan-based rival Gage Growth Corp, backed by prominent cannabis investor Jason Wilde, for around $545 million, the U.S. pot producer said on Wednesday.</p>\n<p>Dealmaking in the U.S. cannabis industry has heated up this year as companies bank on Democrats' promises to reform marijuana laws and potentially legalize the plant at the federal level.</p>\n<p>However, little progress has been made so far and weed stocks have fallen off a cliff in recent months. Gage Growth shares have plunged about 22% up to its last close, since its direct Canadian listing in April.</p>\n<p>Gage Growth, which closed its first day of trading at C$2.89 ($2.29) on April 6, will receive an implied consideration of C$2.66 per share in the merger.</p>\n<p>The combined company will have operations in five U.S. states and Canada, including seven cultivation and processing facilities and 23 operating dispensaries in the two countries, Terrascend said in a statement.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. pot producer Terrascend to buy rival Gage Growth for $545 mln - sources</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. pot producer Terrascend to buy rival Gage Growth for $545 mln - sources\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-01 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sept 1 (Reuters) - Terrascend will buy Michigan-based rival Gage Growth Corp, backed by prominent cannabis investor Jason Wilde, for around $545 million, the U.S. pot producer said on Wednesday.</p>\n<p>Dealmaking in the U.S. cannabis industry has heated up this year as companies bank on Democrats' promises to reform marijuana laws and potentially legalize the plant at the federal level.</p>\n<p>However, little progress has been made so far and weed stocks have fallen off a cliff in recent months. Gage Growth shares have plunged about 22% up to its last close, since its direct Canadian listing in April.</p>\n<p>Gage Growth, which closed its first day of trading at C$2.89 ($2.29) on April 6, will receive an implied consideration of C$2.66 per share in the merger.</p>\n<p>The combined company will have operations in five U.S. states and Canada, including seven cultivation and processing facilities and 23 operating dispensaries in the two countries, Terrascend said in a statement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164890060","content_text":"Sept 1 (Reuters) - Terrascend will buy Michigan-based rival Gage Growth Corp, backed by prominent cannabis investor Jason Wilde, for around $545 million, the U.S. pot producer said on Wednesday.\nDealmaking in the U.S. cannabis industry has heated up this year as companies bank on Democrats' promises to reform marijuana laws and potentially legalize the plant at the federal level.\nHowever, little progress has been made so far and weed stocks have fallen off a cliff in recent months. Gage Growth shares have plunged about 22% up to its last close, since its direct Canadian listing in April.\nGage Growth, which closed its first day of trading at C$2.89 ($2.29) on April 6, will receive an implied consideration of C$2.66 per share in the merger.\nThe combined company will have operations in five U.S. states and Canada, including seven cultivation and processing facilities and 23 operating dispensaries in the two countries, Terrascend said in a statement.","news_type":1},"isVote":1,"tweetType":1,"viewCount":734,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818232208,"gmtCreate":1630412068404,"gmtModify":1676530295824,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>this month need it reach$1 pls......God Allah Buddha Brahman help help.....","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>this month need it reach$1 pls......God Allah Buddha Brahman help help.....","text":"$Sundial Growers Inc.(SNDL)$this month need it reach$1 pls......God Allah Buddha Brahman help help.....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818232208","isVote":1,"tweetType":1,"viewCount":832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364998089552032,"gmtCreate":1730121102013,"gmtModify":1730121106849,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/97f1fb631fa117474fa95250eb4e31cd","width":"870","height":"1772"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/364998089552032","isVote":1,"tweetType":1,"viewCount":906,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"10000000000010968","authorId":"10000000000010968","name":"Tiger_CashBoostAccount","avatar":"https://community-static.tradeup.com/news/ae2d4002ef9664aba005cb3020f416f5","crmLevel":1,"crmLevelSwitch":0,"idStr":"10000000000010968","authorIdStr":"10000000000010968"},"content":"Great job on your latest stock market success! Your commitment to research and analysis is evident in your results. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳💹💰🤩 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","text":"Great job on your latest stock market success! Your commitment to research and analysis is evident in your results. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳💹💰🤩 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","html":"Great job on your latest stock market success! Your commitment to research and analysis is evident in your results. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳💹💰🤩 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":888392488,"gmtCreate":1631431444744,"gmtModify":1676530547708,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"$19X&nbsp;by end year","listText":"$19X&nbsp;by end year","text":"$19X by end year","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888392488","repostId":"2166904370","repostType":4,"isVote":1,"tweetType":1,"viewCount":1092,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":362453877051392,"gmtCreate":1729525626876,"gmtModify":1729525631290,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/f3b0375635ab832502e55203cfa6ae4b","width":"1080","height":"2379"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/362453877051392","isVote":1,"tweetType":1,"viewCount":950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9955145856,"gmtCreate":1675301485576,"gmtModify":1676538990786,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;thanks&nbsp;😊&nbsp;","listText":"&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;thanks&nbsp;😊&nbsp;","text":"thanks 😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9955145856","isVote":1,"tweetType":1,"viewCount":1044,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836618944,"gmtCreate":1629475034188,"gmtModify":1676530054850,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836618944","repostId":"2160471663","repostType":4,"isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}